Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
8.62
-0.09 (-0.98%)
Mar 14, 2025, 10:11 AM EDT - Market open
DAWN Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 131.16 | - | - | - | - | Upgrade
|
| Cost of Revenue | 5.28 | - | - | - | - | Upgrade
|
| Gross Profit | 125.88 | - | - | - | - | Upgrade
|
| Selling, General & Admin | 115.45 | 75.54 | 61.29 | 29.16 | 4.68 | Upgrade
|
| Research & Development | 222.7 | 130.52 | 85.62 | 43.58 | 9.1 | Upgrade
|
| Operating Expenses | 338.15 | 206.06 | 146.91 | 72.74 | 13.78 | Upgrade
|
| Operating Income | -212.27 | -206.06 | -146.91 | -72.74 | -13.78 | Upgrade
|
| Interest Expense | - | - | - | - | -0.03 | Upgrade
|
| Interest & Investment Income | 19.7 | 17.19 | 4.75 | 0 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 109.22 | -0.04 | -0.02 | -0.02 | -30.03 | Upgrade
|
| EBT Excluding Unusual Items | -83.35 | -188.92 | -142.18 | -72.75 | -43.84 | Upgrade
|
| Other Unusual Items | -5 | - | - | - | - | Upgrade
|
| Pretax Income | -88.35 | -188.92 | -142.18 | -72.75 | -43.84 | Upgrade
|
| Income Tax Expense | 7.14 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -95.5 | -188.92 | -142.18 | -72.75 | -43.84 | Upgrade
|
| Minority Interest in Earnings | - | - | - | 2.11 | 3.34 | Upgrade
|
| Net Income | -95.5 | -188.92 | -142.18 | -70.65 | -40.51 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | 99.99 | - | Upgrade
|
| Net Income to Common | -95.5 | -188.92 | -142.18 | -170.64 | -40.51 | Upgrade
|
| Shares Outstanding (Basic) | 93 | 80 | 65 | 37 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 93 | 80 | 65 | 37 | 6 | Upgrade
|
| Shares Change (YoY) | 16.87% | 21.85% | 77.13% | 568.42% | -6.67% | Upgrade
|
| EPS (Basic) | -1.02 | -2.37 | -2.17 | -4.62 | -7.33 | Upgrade
|
| EPS (Diluted) | -1.02 | -2.37 | -2.17 | -4.62 | -7.33 | Upgrade
|
| Free Cash Flow | -80.28 | -147.08 | -109.9 | -48.54 | -13.58 | Upgrade
|
| Free Cash Flow Per Share | -0.86 | -1.84 | -1.68 | -1.31 | -2.46 | Upgrade
|
| Gross Margin | 95.98% | - | - | - | - | Upgrade
|
| Operating Margin | -161.84% | - | - | - | - | Upgrade
|
| Profit Margin | -72.81% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -61.21% | - | - | - | - | Upgrade
|
| EBITDA | -210.71 | -206.03 | -146.85 | -72.72 | -13.77 | Upgrade
|
| EBITDA Margin | -160.65% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 1.56 | 0.04 | 0.06 | 0.02 | 0.02 | Upgrade
|
| EBIT | -212.27 | -206.06 | -146.91 | -72.74 | -13.78 | Upgrade
|
| EBIT Margin | -161.84% | - | - | - | - | Upgrade
|
| Revenue as Reported | 131.16 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.